CONTACT US
Home > Inhibitors/Agonists> > Phendimetrazine tartrate
50-58-8-Phendimetrazine tartrate Phendimetrazine tartrate

Phendimetrazine tartrate

For research use only. Not for therapeutic Use.

  • CAT Number: I034590
  • CAS Number: 50-58-8
  • Molecular Formula: C16H23NO7
  • Molecular Weight: 341.36
  • Purity: 98%
Inquiry Now
Related Small Molecules: hsa-miR-145-5p mimic     β-Zearalenol     Fosphenytoin Sodium    

Phendimetrazine tartrate is discontinued (DEA controlled substance). Phendimetrazine tartrate as dextro isome is an appetite Suppressant (Systemic) .


Catalog Number I034590
CAS Number 50-58-8
Synonyms

Phendimetrazine tartrate; Adipost; Adphen; Alphazine; Bontril; Melfiat; Metra; Phenazine; Statobex

Molecular Formula C16H23NO7
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name D-3,4-Dimethyl-2-phenyl-morpholine tartrate
InChI InChI=1S/C12H17NO.C4H6O6/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11;5-1(3(7)8)2(6)4(9)10/h3-7,10,12H,8-9H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)
InChIKey VEPOHXYIFQMVHW-UHFFFAOYSA-N
SMILES CN1C(C)C(C2=CC=CC=C2)OCC1.OC(C(C(O)=O)O)C(O)=O
Reference

1: Comparison table: some FDA-approved drugs for weight management. Med Lett Drugs Ther. 2018 Jun 4;60(1548):e98-e100. PubMed PMID: 29913464.
2: Diet, drugs, devices, and surgery for weight management. Med Lett Drugs Ther. 2018 Jun 4;60(1548):91-98. PubMed PMID: 29913463.
3: Gomez G, Stanford FC. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes (Lond). 2018 Mar;42(3):495-500. doi: 10.1038/ijo.2017.287. Epub 2017 Nov 20. PubMed PMID: 29151591; PubMed Central PMCID: PMC6082126.
4: Leone O, Agostini V, Foà A, Cerbelli B, di Gioia CRT, Aromatario M, Ciallella C, Lucena J, d’Amati G. Cardiac pathologic findings in 3 unusual cases of sudden cardiac death related to anorexiant drugs. Hum Pathol. 2017 Nov;69:101-109. doi: 10.1016/j.humpath.2017.09.014. Epub 2017 Oct 9. PubMed PMID: 29024685.
5: Velazquez A, Apovian CM. Pharmacological management of obesity. Minerva Endocrinol. 2018 Sep;43(3):356-366. doi: 10.23736/S0391-1977.17.02654-2. Epub 2017 Apr 28. PubMed PMID: 28462579.
6: Solis E Jr, Suyama JA, Lazenka MF, DeFelice LJ, Negus SS, Blough BE, Banks ML. Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters. Sci Rep. 2016 Aug 12;6:31385. doi: 10.1038/srep31385. PubMed PMID: 27514281; PubMed Central PMCID: PMC4981850.
7: Czoty PW, Blough BE, Fennell TR, Snyder RW, Nader MA. Attenuation of cocaine self-administration by chronic oral phendimetrazine in rhesus monkeys. Neuroscience. 2016 Jun 2;324:367-76. doi: 10.1016/j.neuroscience.2016.03.002. Epub 2016 Mar 7. PubMed PMID: 26964683; PubMed Central PMCID: PMC4838503.
8: Bolin BL, Stoops WW, Sites JP, Rush CR. Abuse Potential of Oral Phendimetrazine in Cocaine-dependent Individuals: Implications for Agonist-like Replacement Therapy. J Addict Med. 2016 May-Jun;10(3):156-65. doi: 10.1097/ADM.0000000000000206. PubMed PMID: 26933876; PubMed Central PMCID: PMC4880531.
9: Stoops WW, Strickland JC, Hays LR, Rayapati AO, Lile JA, Rush CR. Safety and tolerability of intranasal cocaine during phendimetrazine maintenance. Psychopharmacology (Berl). 2016 Jun;233(11):2055-2063. doi: 10.1007/s00213-016-4260-7. Epub 2016 Mar 1. PubMed PMID: 26932737; PubMed Central PMCID: PMC4864128.
10: Rodríguez JE, Campbell KM. Past, Present, and Future of Pharmacologic Therapy in Obesity. Prim Care. 2016 Mar;43(1):61-7, viii. doi: 10.1016/j.pop.2015.08.011. Epub 2016 Jan 12. Review. PubMed PMID: 26896200.
11: Bauer CT, Negus SS, Blough BE, Banks ML. Cocaine-like discriminative stimulus effects of phendimetrazine and phenmetrazine in rats. Behav Pharmacol. 2016 Apr;27(2-3 Spec Issue):192-5. doi: 10.1097/FBP.0000000000000225. PubMed PMID: 26866973; PubMed Central PMCID: PMC4779707.
12: Cho AR, Yoon YH. Central Retinal Vein Occlusion Noted 2 Days After Use of Phendimetrazine as an Appetite Suppressant. JAMA Ophthalmol. 2016 Apr;134(4):463-4. doi: 10.1001/jamaophthalmol.2015.5966. PubMed PMID: 26846182.
13: McLaughlin G, Morris N, Kavanagh PV, Dowling G, Power JD, Twamley B, O’Brien J, Talbot B, Sitte HH, Brandt SD. Test purchase, synthesis and characterization of 3-fluorophenmetrazine (3-FPM) and differentiation from its ortho- and para-substituted isomers. Drug Test Anal. 2017 Mar;9(3):369-377. doi: 10.1002/dta.1945. Epub 2016 Jan 26. PubMed PMID: 26810957.
14: Choi H, Kim S, Ahn S, Chang H, Lee S, Lee Y. Development of an analytical method for simultaneous detection of psychotropic phenylalkylamines in hair by LC-MS/MS with a multi-mode reversed-phase column using pH gradient elution. Forensic Sci Int. 2016 Feb;259:69-76. doi: 10.1016/j.forsciint.2015.12.016. Epub 2015 Dec 23. PubMed PMID: 26760907.
15: Ryazanova O, Zozulya V, Voloshin I, Dubey L, Dubey I, Karachevtsev V. Spectroscopic Studies on Binding of Porphyrin-Phenazine Conjugate to Four-Stranded Poly(G). J Fluoresc. 2015 Jul;25(4):1013-21. doi: 10.1007/s10895-015-1585-2. Epub 2015 Jun 16. PubMed PMID: 26076929.
16: Konstantinos L, Karavis M, Mastorakos G, Valsamakis G. New Molecular Targets for the Pharmacotherapy of Obesity. 2015 Apr 8. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from http://www.ncbi.nlm.nih.gov/books/NBK279143/ PubMed PMID: 25905366.
17: Joo JK, Lee KS. Pharmacotherapy for obesity. J Menopausal Med. 2014 Dec;20(3):90-6. doi: 10.6118/jmm.2014.20.3.90. Epub 2014 Dec 24. Review. PubMed PMID: 25580419; PubMed Central PMCID: PMC4286660.
18: Hutsell BA, Negus SS, Banks ML. A generalized matching law analysis of cocaine vs. food choice in rhesus monkeys: effects of candidate ‘agonist-based’ medications on sensitivity to reinforcement. Drug Alcohol Depend. 2015 Jan 1;146:52-60. doi: 10.1016/j.drugalcdep.2014.11.003. Epub 2014 Nov 20. PubMed PMID: 25439054; PubMed Central PMCID: PMC4272824.
19: Strano-Rossi S, Odoardi S, Castrignanò E, Serpelloni G, Chiarotti M. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) determination of stimulants, anorectic drugs and phosphodiesterase 5 inhibitors (PDE5I) in food supplements. J Pharm Biomed Anal. 2015 Mar 15;106:144-52. doi: 10.1016/j.jpba.2014.06.011. Epub 2014 Jun 14. PubMed PMID: 24996684.
20: Howell LL, Negus SS. Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. Adv Pharmacol. 2014;69:129-76. doi: 10.1016/B978-0-12-420118-7.00004-4. Review. PubMed PMID: 24484977; PubMed Central PMCID: PMC4406244.

Request a Quote